STAT+: GSK lays out plans to cut costs, pursue more late-stage drug trials

MAP Verified Summary — reported by STAT News

New CEO Luke Miels used the company's earnings report to outline a strategy that he said could put the company on a path to long-term growth.

This story was scored across MAP’s five-signal verification framework — Context, Presentation, References, Visibility, and Comparison — as part of Media Alert Press’s independent media credibility index. Read the full original story at STAT News →